Proteolytic enzymes modulate the adhesion molecule CD44 on malignant cells in vitro

International Journal of Immunotherapy

Volumn 13, Issue 3-4, 1997, Pages 111-119

  Gebauer, F ^a   Micheel, B ^b,c   Stauder, G ^d   Ransberger, K ^d   Kunze, R ^a  

^a Imtox Inc   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Medical Enzyme Research Society   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMELAIN; CHYMOTRYPSIN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; PAPAIN; PROTEINASE;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CELL SURFACE; CONTROLLED STUDY; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; LEUKEMIA; MELANOMA; METASTASIS;

EID: 0031399462     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gunthert U., Hofmann M , Rudy W., et al A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13, 1991
2. Seiter S., Arch R , Reber S , et al. Prevention of tumor metastasis formation by antivariant CD44. J. Exp. Med. 177, 443, 1993.
3. Gunthert U CD44: a multitude of isoforms with diverse functions Curr Top. Microbiol. Immunol , 184, 47, 1993.
4. Sherman L , Sleeman J., Herrlich P , Ponta H., Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol., 6, 726, 1994.
5. Toyama Sonmachi N , Miyasaka M. A novel ligand for CD44 is sulfated proteoglycan. Int Immunol., 6, 655, 1994.
6. Zoller M. CD44. physiological expression of distinct isoforms as evidence for organ-specific metastasis formation J Mol Med 73, 425, 1995.
7. Herrlich P., Zoller M , Pals S T , Ponta H. CD44 splice variants metastases meet lymphocytes. Immunol. Today, 14, 395, 1993
8. Terpe H.J., Koopmann R., Imhof B.A , Gunthert U Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J. Pathol., 174, 89, 1994.
9. Rodriguez C , Monges G , Rouanet P., Dutrillaux B , Lefrancois D , Theillet C CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants Int. J. Cancer 64, 347, 1995
10. Friedrichs K , Kugler G., Franke F., et al. CD44 isoforms in prognosis of breast cancer Lancet. 345, 1237, 1995
11. Kaufmann M , Heider K H , Sinn H.P , von Minckwritz G , Ponta H , Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345, 615, 1995
12. Manten H.E., Danen E.H., Smit L., et al. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer, 64, 182, 1995
13. Munzig E., Eckert K., Harrach T , Graf H., Maurer H.R. Bromelin protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells FEBS Lett , 351, 215, 1994
14. Hale L P , Haynes B.F Bromelin treatment of human T-cells removes CD44, CD45RA, E2/MIC2, CD6 CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-meaiated T-cell activation J Immunol, 149, 3809, 1992.
15. Bazil V , Strominger J L Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and D16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J. Immunol., 152, 1314, 1994.
16. Jutila M.A., Kishimoto T.K., Finken M Low-dose chymotrypsin treatment inhibits neutrophil migration into sites of inflammation in vivo: effects on Mac-1 and MEL-14 adhesion protein and function. Cell Immunol., 132, 201, 1991.
17. 2-macroglobuline trypsin complex. 2nd Int. Gong. On Biological Response Modifiers, (Jan 29-31, San Diego, California) 1993, Abstr 22
18. Renner C., Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies Immunol. Rev., 145, 179, 1995.
19. Jantscheff P., Winkler L., Karawajew L., Kaiser G., Bottger V., Micheel B. Hybrid hybridomas producing bispecific antibodies to CEA and peroxidase isolated by a combination of HAT medium selection and fluorescence activated cell sorting J Immunol Methods, 163, 91, 1993.